The Effect of Some Alpha-adrenoceptor Antagonists on Spontaneous Myogenic Activity in the Rat Portal Vein and the Putative Involvement of ATP-sensitive K+ Channels
Overview
Affiliations
In the present study we showed that the alpha-adrenoceptor antagonists phentolamine, yohimbine, prazosin, corynanthine and idazoxan, when cumulatively applied in high concentrations (1-100 mumol/l), can increase spontaneous myogenic activity in the rat portal vein. 5-Methyl-urapidil and rauwolscine were ineffective in this respect. Pretreatment with phenoxybenzamine in a concentration of 1 mumol/l (20 min), which results in alkylation of all functional alpha-adrenoceptors in the rat portal vein, was unable to antagonize the increase in spontaneous myogenic activity elicited by phentolamine. Antazoline (1-100 mumol/l), a H1 antagonist and 2-substituted imidazoline which is devoid of alpha-adrenoceptor blocking properties, exhibited similar effects on spontaneous myogenic activity as its structurally closely related analogue phentolamine. Since phentolamine is reported to interact with ATP-sensitive K+ channels we investigated the role of K+ channels in more detail. The K+ channel openers cromakalim and diazoxide elicited a decrease in spontaneous myogenic activity. Glibenclamide (0.3-3 mumol/l), a selective blocker of ATP-sensitive K+ channels in cardiac and pancreatic tissues, and phentolamine (1-10 mumol/l) shifted the concentration-response curves of cromakalim and diazoxide concentration dependently to the right. Yohimbine showed only a modest effect in the highest concentration (100 mumol/l) applied. E-4031 (0.01-0.3 mumol/l), a sotalol derivative and one of the most selective blockers of the delayed rectifier current (Ik) in cardiac tissue, was a potent contractile agent when added to the rat portal vein in the same way as the alpha-adrenoceptor antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)
Changes of imidazoline receptors in spontaneously hypertensive rats.
Mar G, Chou M, Chung H, Chiu N, Chen M, Cheng J Int J Exp Pathol. 2012; 94(1):17-24.
PMID: 23176371 PMC: 3575869. DOI: 10.1111/iep.12000.
Minyan W, Dunn W, Blaylock N, Chan S, Wilson V Br J Pharmacol. 2001; 132(7):1359-63.
PMID: 11264227 PMC: 1572690. DOI: 10.1038/sj.bjp.0703949.
Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine.
Allan D, Penner S, Smyth D Br J Pharmacol. 1996; 117(1):29-34.
PMID: 8825339 PMC: 1909361. DOI: 10.1111/j.1476-5381.1996.tb15150.x.
Ibbotson T, Edwards G, Noack T, Weston A Br J Pharmacol. 1993; 108(4):991-8.
PMID: 8485637 PMC: 1908130. DOI: 10.1111/j.1476-5381.1993.tb13496.x.
Ibbotson T, Edwards G, Weston A Br J Pharmacol. 1993; 110(4):1556-64.
PMID: 8306101 PMC: 2175856. DOI: 10.1111/j.1476-5381.1993.tb14001.x.